-
Mycobacterium Tuberculosis(Sputum/Tongue swab sample)
Tuberculosis (TB), caused by Mycobacterium tuberculosis, primarily affects the lungs, with around 10 million new cases annually as of July 2024. Traditional testing methods are often impractical for rapid diagnosis. Our Mycobacterium Tuberculosis Nucleic Acid Test Card offers a user-friendly solution for detecting MTBC DNA in sputum or tongue swab samples, enabling timely diagnosis and management.¥ 0.00More >
-
SARS-CoV-2/FIu A/Flu B
With the rise of respiratory illnesses like COVID-19, Flu A, and Flu B, efficient and accurate testing is vital. As of July 2024, SARS-CoV-2 has caused over 760 million cases worldwide, and seasonal flu affects millions each year. Quick, precise diagnosis is key to effective management. Traditional methods can be cumbersome for rapid, frequent testing.
This kit provides a streamlined solution for in vitro detection of SARS-CoV-2, Influenza A, and Influenza B RNA in nasal swab samples.¥ 0.00More >
-
HPV 16/18/45
HPV types 16, 18, and 45 are linked to various cancers, notably cervical cancer, with types 16 and 18 causing about 70% of cases. With over 600,000 new cervical cancer cases annually as of July 2024, early screening is crucial. Traditional methods may be slow, delaying follow-up and treatment.
This kit offers rapid detection of HPV types 16, 18, and 45 DNA in cervical and vulvovaginal swabs, aiding early diagnosis and cancer prevention.¥ 0.00More >
-
SARS-CoV-2
Traditional large testing equipment is often impractical for frequent, quick tests. Quick and accurate testing methods are essential for timely diagnosis and effective management of COVID-19 cases. Accurate COVID-19 diagnosis is crucial due to its global impact and high transmission rates.
This kit provides in vitro qualitative detection of the N gene and ORF1ab gene of SARS-CoV-2 in nasal swabs from suspected COVID-19 cases.¥ 0.00More >
-
Pluslife Wins the "2024 Medical Health Corporate Responsibility Model Award," Leading New Breakthroughs in Tuberculosis Control
Pluslife won the "2024 Medical Health Corporate Responsibility Model Award" at the 14th Philanthropy Festival and 2024 ESG Impact Summit, recognizing its outstanding contributions to global tuberculosis control and corporate social responsibility.
2025-01-16
-
Pluslife Advances Global TB Testing Innovation and Expands Development of Drug-Resistant TB Products
Pluslife is accelerating efforts to provide cost-effective TB diagnostic tools, enhancing accessibility in high-burden areas, and helping to curb TB's spread globally.
2024-12-04
-
Advancing TB Diagnostics: Pluslife's Commitment to Accessible Solutions
Pluslife’s TB detection product has surpassed the World Health Organization’s (WHO) stringent requirements for 'near POC non-sputum diagnostic' platforms.
2024-11-25
